FDA approves a generic form of rosuvastatin which is potent in controlling lipid levels in the blood and is cost effective.

- FDA approves generic rosuvastatin.
- Rosuvastatin lowers lipid levels in the blood.
- It can be used in the treatment for hypertriglyceridimia, type III hyperlipoproteinemia and homozygous familial hypercholesterolemia.
- Hypertriglyceridimia in adults along with diet control
- Type III Hyperlipoproteinemia along with diet control
- Homozygous Familial Hypercholesterolemia in adults, alone or along with other cholesterol treatments
Mode of Action of Rosuvastatin
Rosuvastatin belongs to a group of drugs called statins. Rosuvastatin and other statins inhibit the enzyme HMG CoA reductase that is responsible for the formation of cholesterol.
The generic form of rosuvastatin called Crestor from Watson Pharmaceuticals is now approved by the U.S. Food and Drug Administration to lower the lipid levels.





The Ability of Rosuvastatin to Lower Lipid Levels
Scientists Adams SP and colleagues carried out a study titled “Lipid-lowering Efficacy of Rosuvastatin” which was published in the Cochrane Database of Systematic Reviews 2014. This study aimed to understand the efficacy of the drug rosuvastatin on blood lipids.
The effect of varying doses of rosuvastatin were studied on the level of:
- High Density Lipoprotein (HDL)
- Low Density Lipoprotein (LDL)
- Serum total cholesterol
- Non- HDL cholesterol
- Triglycerides
Results of the Study- Benefits of Rosuvastatin
- LDL-cholesterol decreased by 46% to 55% with an intake of 10-40 mg of rosuvastatin per day.
- There was dose dependent effect of rosuvastatin on the levels of
- Serum cholesterol
- LDL-cholesterol
- Non- HDL cholesterol
- Rosuvastatin was found to be three times more effective than atorvastatin in lowering LDL-cholesterol.
- HDL-cholesterol was increased by 7% with the use of rosuvastatin, but this was not dose dependant.
- Headache
- Muscle pain
- Weakness
- Nausea
- Abdominal pain
References:
- FDA approves first generic Crestor
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498373.htm - Lipid-lowering efficacy of rosuvastatin.
https://www.ncbi.nlm.nih.gov/pubmed/25415541